Literature DB >> 5050315

Bile acid metabolism in patients with cirrhosis. II. Cholic and chenodeoxycholic acid metabolism.

Z R Vlahcevic, P Juttijudata, C C Bell, L Swell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5050315

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  23 in total

1.  Increased prevalence of intestinal inflammation in patients with liver cirrhosis.

Authors:  Osamu Saitoh; Kazunori Sugi; Keishi Lojima; Hisashi Matsumoto; Ken Nakagawa; Masanobu Kayazawa; Seigou Tanaka; Tsutomu Teranishi; Ichiro Hirata
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  Biliary squalene levels in hepatobiliary disease.

Authors:  Y Nosaka; Y Yamanishi; C Hirayama
Journal:  Gastroenterol Jpn       Date:  1985-08

3.  The metabolism of steroids in the fatty liver induced by orotic acid feeding.

Authors:  M Carrella; I Björkhem; J A Gustafsson; K Einarsson; K Hellström
Journal:  Biochem J       Date:  1976-07-15       Impact factor: 3.857

4.  Altered bile acid metabolism in primary biliary cirrhosis.

Authors:  R Raedsch; B H Lauterburg; A F Hofmann
Journal:  Dig Dis Sci       Date:  1981-05       Impact factor: 3.199

5.  Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.

Authors:  G Mazzella; P Parini; F Bazzoli; N Villanova; D Festi; R Aldini; A Roda; A Cipolla; C Polimeni; D Tonelli
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

Review 6.  Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects.

Authors:  Monica Acalovschi
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

7.  Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.

Authors:  A Lanzini; M G De Tavonatti; B Panarotto; S Scalia; A Mora; F Benini; O Baisini; F Lanzarotto
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

8.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Endogenous bile acid tolerance test for liver function.

Authors:  M van Blankenstein; M Frenkel; J W van den Berg; F J ten Kate; E P Bosman-Jacobs; A C Touw-Blommesteyn
Journal:  Dig Dis Sci       Date:  1983-02       Impact factor: 3.199

10.  Biliary lipids, faecal steroids, and liver function in patients with chronic active hepatitis and primary biliary cirrhosis: significance of hepatic orcein-stained complexes.

Authors:  Y A Kesäniemi; T A Miettinen; M P Salaspuro
Journal:  Gut       Date:  1981-07       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.